Dysbiosis, or an imbalance in gut microbiota, is associated with metabolic diseases, especially T2DM, and can cause changes in the signaling pathways of intestinal hormone secretion, leading to various health problems [156]
Must come from complete sources
Key Takeaway GLP-1 medications may be changing the weight loss landscape, but nutrition still matters enormously
Our data also document changes in other specific hypothalamic signaling pathways that may be related to the metabolic effects of the multi-agonist, as is the case of calcium/calmodulin-dependent protein kinase 2 (CAMK2)
If finalized, this means 503B outsourcing facilities - which compound drugs in larger batches for healthcare facilities and telehealth platforms - would lose the legal basis to compound these specific GLP-1 medications at scale
Sources: Does a beneficiary need to meet the Medicare GLP-1 Bridge clinical criteria at the time of the prior authorization request, or at the time they first initiated GLP-1 therapy? What do beneficiaries need to do now if interested in the Medicare GLP-1 Bridge? and Are TRICARE For Life beneficiaries eligible to receive GLP-1 drugs furnished via the Medicare GLP-1 Bridge? on Reply It would be interesting to know why the delay
